Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tooth hydroxyapatite is the principal inorganic mineral component of human dental enamel and dentin, comprising 70–95% of their mass. It is a crystalline calcium phosphate compound with the chemical formula Ca₁₀(PO₄)₆(OH)₂. Hydroxyapatite provides the hardness and structural resiliency of teeth, forming densely packed rods (and interrods) surrounded by a small organic matrix and water[2][4][5]. Enamel hydroxyapatite is highly resistant to mechanical wear but vulnerable to acidic dissolution (demineralization) during caries and erosion. Remineralization therapies—including toothpastes and dental treatments—sometimes employ biomimetic or synthetic hydroxyapatite to replace lost mineral content, leveraging its chemical similarity and high biocompatibility. Hydroxyapatite is a mineral and not a protein, receptor, or enzyme, and therefore is not considered a therapeutic target in the pharmacological sense; it is instead a substrate for biomaterials or restorative interventions, not a direct drug target[1][3][5].
Null (not a direct drug target; mechanistically, exogenous HAP can promote remineralization by direct mineral deposition and occlusion of enamel micropores[1][3][5].)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tooth hydroxyapatite (HAP).